featured
Atezolizumab and Chemotherapy for Advanced or Recurrent Endometrial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol 2024 Aug 02;[EPub Ahead of Print], N Colombo, E Biagioli, K Harano, F Galli, E Hudson, Y Antill, CH Choi, M Rabaglio, F Marmé, C Marth, G Parma, L Fariñas-Madrid, S Nishio, K Allan, YC Lee, E Piovano, B Pardo, S Nakagawa, J McQueen, C Zamagni, L Manso, K Takehara, G Tasca, A Ferrero, G Tognon, AA Lissoni, M Petrella, ME Laudani, E Rulli, S Uggeri, MP Barretina GinestaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.